Aksys to trade on Nasdaq Capital Market

By Jennifer Chiou

New York, Feb. 13 - Aksys, Ltd. said it received notice from the Nasdaq listing qualifications panel that its stock will be moved to the Nasdaq Capital Market starting Tuesday. It is currently trading on the Nasdaq National Market.

The company's continued listing is contingent upon an application and review process and Aksys noted that it believes it is in compliance with listing standards.

"Although our journey to regain compliance with Nasdaq's stringent listing requirements has been lengthy, we are pleased by recent developments, which have enabled Aksys to transfer to the Nasdaq Capital Market," said president and chief executive officer Bill Dow in a news release.

"Our continued listing will allow us the flexibility to continue to achieve our goal of creating long-term shareholder value."

On Feb. 10, the company said it was informed that it regained compliance with Nasdaq's listing requirement that its stock close at $1.00 or greater for at least 10 consecutive days. In December, Aksys learned it had until June 14 to regain compliance with the minimum bid price listing standard.

The Lincolnshire, Ill., producer of hemodialysis products provides for kidney failure patients.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.